← All Cvrx, INC filings

Cvrx, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CVRX
Cvrx, INC
10-K: CVRx Reports 10% Revenue Growth, Expands Heart Failure Market
CVRx, Inc. reported a 10% increase in revenue to $56.7 million for fiscal year 2025, driven by U.S. sales growth and expanded market opportunities for its Barostim therapy.
NASDAQ
CVRX
Cvrx, INC
10-K: CVRx Reports Increased Revenue and Expanded Market Opportunity in 2024 10-K Filing
CVRx's 2024 10-K filing reveals a revenue increase to $51.3 million and an expanded market opportunity for its Barostim therapy.
NASDAQ
CVRX
Cvrx, INC
10-K: CVRx, Inc. Reports Full Year 2023 Results and Provides Business Update in 10-K Filing
CVRx, Inc. reported a revenue increase to $39.3 million and a net loss of $41.2 million for the year ended December 31, 2023, highlighting growth in U.S. sales of its Barostim device.